Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $131.00 at Citigroup

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its target price lowered by Citigroup from $136.00 to $131.00 in a report released on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Stifel Nicolaus set a $131.00 price objective on shares of Rhythm Pharmaceuticals in a report on Thursday, February 26th. HC Wainwright cut their target price on Rhythm Pharmaceuticals from $125.00 to $110.00 and set a “buy” rating on the stock in a report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 22nd. Royal Bank Of Canada decreased their price target on Rhythm Pharmaceuticals from $140.00 to $130.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Citizens Jmp lowered their price objective on Rhythm Pharmaceuticals from $176.00 to $152.00 and set a “market outperform” rating on the stock in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.75.

Rhythm Pharmaceuticals Stock Down 3.1%

NASDAQ RYTM opened at $87.68 on Tuesday. The stock has a market capitalization of $5.99 billion, a PE ratio of -28.19 and a beta of 2.06. The company has a 50 day moving average price of $99.77 and a two-hundred day moving average price of $102.81. Rhythm Pharmaceuticals has a 12-month low of $45.90 and a 12-month high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The company had revenue of $57.25 million during the quarter, compared to the consensus estimate of $56.16 million. During the same period in the previous year, the firm posted ($0.72) earnings per share. The company’s revenue for the quarter was up 36.9% compared to the same quarter last year. As a group, equities analysts anticipate that Rhythm Pharmaceuticals will post -4.32 EPS for the current year.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, CAO Christopher Paul German sold 5,614 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total transaction of $502,789.84. Following the completion of the transaction, the chief accounting officer owned 160 shares of the company’s stock, valued at $14,329.60. The trade was a 97.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $101.26, for a total transaction of $444,025.10. Following the sale, the chief financial officer owned 110,512 shares of the company’s stock, valued at $11,190,445.12. This trade represents a 3.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 27,267 shares of company stock worth $2,719,955 in the last quarter. Insiders own 6.10% of the company’s stock.

Institutional Trading of Rhythm Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. RA Capital Management L.P. lifted its holdings in shares of Rhythm Pharmaceuticals by 17.3% during the fourth quarter. RA Capital Management L.P. now owns 6,666,837 shares of the company’s stock worth $713,618,000 after buying an additional 985,478 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Rhythm Pharmaceuticals by 24.3% in the fourth quarter. Vanguard Group Inc. now owns 6,210,916 shares of the company’s stock worth $664,816,000 after acquiring an additional 1,214,489 shares during the last quarter. State Street Corp grew its stake in shares of Rhythm Pharmaceuticals by 8.4% in the fourth quarter. State Street Corp now owns 2,198,615 shares of the company’s stock worth $235,340,000 after acquiring an additional 169,964 shares during the last quarter. Federated Hermes Inc. increased its position in Rhythm Pharmaceuticals by 2.5% during the third quarter. Federated Hermes Inc. now owns 1,727,885 shares of the company’s stock worth $174,499,000 after acquiring an additional 41,391 shares during the period. Finally, Westfield Capital Management Co. LP increased its position in Rhythm Pharmaceuticals by 21.5% during the second quarter. Westfield Capital Management Co. LP now owns 1,629,468 shares of the company’s stock worth $102,966,000 after acquiring an additional 288,376 shares during the period.

Rhythm Pharmaceuticals News Roundup

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Company delivered solid revenue growth and a Q4 beat (FY25 revenue $194.8M, +50% year/year), which supports continued commercial demand for IMCIVREE (setmelanotide) and underpins longer-term upside. Article Title
• Positive Sentiment: Company highlights post‑hoc analyses showing statistically significant BMI reductions at 52 weeks in patients with heterozygous POMC/PCSK1 and SRC1 (NCOA1) variants — these subgroup signals could support label expansion or targeted use, which investors may view as constructive if regulators/market accept the evidence. Article Title
• Neutral Sentiment: Company-hosted transcript and slide materials on the EMANATE topline results are available for investors evaluating the detailed data and management commentary; these provide context for both the misses and the subgroup findings. Transcript Slides
• Negative Sentiment: Topline EMANATE results showed the experimental obesity program did not meet several pre‑specified primary endpoints across four substudies — the primary failure is the main driver of near‑term negative sentiment and regulatory scrutiny. Reuters
• Negative Sentiment: Multiple major brokerages trimmed price targets today (Citigroup, RBC, Citizens JMP, BofA, Morgan Stanley, Needham). Although most retained buy/outperform ratings, the lower targets signal reduced near‑term upside expectations and likely contributed to selling pressure. Benzinga TickerReport

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.